Generic drug warning lawsuits
PLIVA v. Mensing
In brief
The Supreme Court overturned the Eighth Circuit’s judgment and sent Mensing’s case back for further proceedings, without resolving the final outcome of her claims.
- Where it stands
- Decided
Decided 5-4 · June 23, 2011 · Opinion by Justice Thomas
- What it’s about
- Gladys Mensing sued makers of generic metoclopramide, alleging they failed to warn about dangerous side effects; the dispute was whether federal rules requiring generic labels to match brand-name labels barred such state-law claims.
- Who it affects
- The case returned to the Eighth Circuit, leaving Mensing’s warning claims against the generic-drug makers unresolved by the Supreme Court’s action.
Summary: written with AI from the case record.
What it's about
The Supreme Court overturned the Eighth Circuit’s judgment and sent the case back to that court (remanded).
The dispute centered on whether federal rules requiring generic labels to match brand-name labels barred state-law failure-to-warn claims.
Question presented
Can generic drug makers be sued for not warning about potentially dangerous side effects on their drug labels even when they follow federal rules that only require their labels to match those of their brand-name equivalents?
What the Court decided
Holding
The judgment is reversed, and the cases are remanded. —————— * Together with No. 09–1039, Actavis Elizabeth, LLC v. Mensing, also on certiorari to the same court, and No. 09–1501, Actavis, Inc. v. Demahy, on certiorari to the United States Court of Appeals for the Fifth Circuit. 588 F. 3d 603 and 593 F. 3d 428, reversed and remanded.
- Result
- Reversed
The vote
From the opinions
“Until today, the mere possibility of impossibility had not been enough to establish pre-emption.”
What's next
The Eighth Circuit will handle the case again. The Supreme Court’s action did not decide whether Mensing’s warning claims ultimately succeed.
Documents
Opinions
Audio
Docket activity
New analysis added
AI analysis generated: Case Briefing
New analysis added
AI analysis generated: Impact Analysis
AI analysis generated: Opinion Summary
Show 5 moreShow fewer
AI analysis generated: Decision Record
Case data updated: summary, question_presented, generation_metadata
Case data updated: question_presented, extraction_metadata
Audio Recording added: Oral Arguments - Mensing
Opinion added: Mensing
More questions
- What did Justice Sotomayor argue?
- She argued that generic makers could propose label changes to the Food and Drug Administration (FDA); if the FDA changed the brand-name label, matching generic labels could change too, allowing compliance with both federal rules and state warning duties.
Sources
Primary materials plus reporting. Best-effort analysis: this explainer relies on a mix of primary materials and trusted secondary sources. Official filings and opinions remain authoritative.